BIIB

Biogen Inc (BIIB) is the lead sponsor of 39 active clinical trials listed on ClinicalTrials.gov^[5], including 15 Phase 3^[1], 4 Phase 2^[2], 7 Phase 1^[3], 1 Phase 4^[4].

Trial NCT03958877^[6] evaluates BIIB017 (peginterferon beta-1a) in Multiple Sclerosis, Relapsing-Remitting with a target enrollment of 152 participants. Trial NCT06953583^[7] evaluates Omaveloxolone in Friedreich Ataxia with a target enrollment of 255 participants. Trial NCT04961567^[8] evaluates Litifilimab in Lupus Erythematosus, Systemic with a target enrollment of 562 participants.

BIIB has 1 Form 4 insider filing recorded at the SEC in the past 30 days^[9].